GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of VersantisGlobeNewsWire • 09/29/22
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 09/28/22
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver DiseasesGlobeNewsWire • 09/19/22
FDA Grants GENFIT's GNS561 Orphan Drug Designation for the Treatment of CholangiocarcinomaGlobeNewsWire • 09/13/22
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)GlobeNewsWire • 05/11/22
GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022GlobeNewsWire • 04/29/22
GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory DocumentsGlobeNewsWire • 04/20/22
Genfit SA (GNFT) CEO Pascal Prigent on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/08/22
GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/07/22
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 01/11/22
GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go GangbustersInvestorPlace • 12/17/21
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment HopefulBenzinga • 12/17/21
On heels of global strategic partnership announced today, GENFIT acquires rights to novel assetGlobeNewsWire • 12/17/21
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global PartnershipBusiness Wire • 12/17/21
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnershipGlobeNewsWire • 12/17/21
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology's Unique Performance in Identifying Patients with “at-risk” NASHGlobeNewsWire • 11/18/21